Skip to main content

Featured

Canada’s Inflation Cools to 2.2% in October Amid Cheaper Gas and Groceries

  Motorists fuel up at an ONroute gas station near Maple, Ont., on April 1, 2025. Lower gas prices helped bring overall inflation down in October, Statistics Canada says. Canada’s annual inflation rate eased to 2.2% in October , down from 2.4% in September. The slowdown was largely driven by falling gasoline and grocery prices, offering some relief to consumers after months of persistent cost pressures. Key Drivers of the Decline Gasoline prices dropped 4.8% month-over-month , as retailers switched to cheaper winter fuel blends and global crude oil prices fell due to oversupply concerns. Grocery prices fell 0.6% in October , marking the largest monthly decline since September 2020. Annual grocery inflation cooled to 3.4% , down from 4% in September, with lower costs for processed foods and fresh vegetables offsetting higher prices for chicken. Excluding gasoline, the Consumer Price Index (CPI) rose 2.6% year-over-year , showing that underlying inflationary pressures remain....
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment